Corresponding Author: Sunil V. Rao, MD, Duke Clinical Research Institute, 508 Fulton St (111A), Durham, NC 27705 (sunil.rao@duke.edu).
Author Contributions: Dr Rao had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Rao, Weintraub, Roe.
Acquisition of data: Kaltenbach, Weintraub, Peterson.
Analysis and interpretation of data: Rao, Kaltenbach, Weintraub, Roe, Brindis, Rumsfeld, Peterson.
Drafting of the manuscript: Rao.
Critical revision of the manuscript for important intellectual content: Kaltenbach, Weintraub, Roe, Brindis, Rumsfeld, Peterson.
Statistical analysis: Rao, Kaltenbach, Peterson.
Obtained funding: Rao, Roe, Peterson.
Administrative, technical, or material support: Rao, Weintraub, Rumsfeld.
Study supervision: Rao, Roe, Brindis, Peterson.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Rao reported receiving consulting fees from Terumo Medical, The Medicines Company, AstraZeneca, and Zoll and research funding from Ikaria, sanofi-aventis, and Terumo Medical. Dr Weintraub reported receiving research grants from Otsuka, AstraZeneca, Bristol-Myers Squibb, sanofi-aventis, and Abbott; receiving consultant fees from Eli Lilly, Bristol-Myers Squibb, Shionogi, sanofi-aventis, Cardionet, and Daiichi-Sankyo; and providing expert testimony in cases involving Bayer and Pfizer. Dr Roe reported receiving research funding from Eli Lilly, Roche, Novartis, Merck-Schering Plough, Bristol-Myers Squibb, the American College of Cardiology, and the American Heart Association and consulting fees/honoraria from GlaxoSmithKline, KAI Pharmaceuticals, Novartis, Eli Lilly, Bristol-Myers Squibb, sanofi-aventis, Merck, Orexigen, Helsinn Pharmaceuticals, Regeneron, and AstraZeneca. Dr Rumsfeld reported being chief science officer for the National Cardiovascular Data Registry. Dr Peterson reported receiving research grants from Bristol-Myers Squibb, sanofi-aventis, Eli Lilly, Schering Plough/Merck, Johnson & Johnson, and St Jude Inc and consultant fees from Bayer and Pfizer. No other disclosures were reported.
Funding/Support: This analysis was funded by the American College of Cardiology. This research was supported by the American College of Cardiology Foundation National Cardiovascular Data Registry (NCDR).
Role of the Sponsor: The funding organization had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.
Disclaimer: Dr Peterson, Contributing Editor, JAMA, was not involved in the editorial review of or decision to publish this article. The views expressed in this article represent those of the authors and do not necessarily represent the American College of Cardiology Foundation or the Society for Cardiac Angiography and Interventions, which cosponsor the National Cardiovascular Data Registry.
Online-Only Material: An Author Audio Interview is available here.
Additional Contributions: We thank Erin LoFrese, MS, Duke Clinical Research Institute, for editorial assistance. Ms LoFrese did not receive compensation for her assistance apart from her employment at Duke Clinical Research Institute.